Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Positive Discussion at Fidaxomicin FDA AdCom Meeting, Expect Approval Next Month
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $19.
Needham analyst says, "An FDA Advisory Committee ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "An FDA Advisory Committee ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
